Virpax Pharmaceuticals Stock Retained Earnings
| VRPXDelisted Stock | USD 0.25 0.04 19.05% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Virpax Pharmaceuticals' long-term financial health and intrinsic value.
Virpax |
Virpax Pharmaceuticals Company Retained Earnings Analysis
Virpax Pharmaceuticals' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Virpax Pharmaceuticals Retained Earnings | (71.61 B) |
Most of Virpax Pharmaceuticals' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Virpax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Virpax Pharmaceuticals has a Retained Earnings of (71.61 Billion). This is 7788.91% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is significantly higher than that of the company.
Virpax Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Virpax Pharmaceuticals' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Virpax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Virpax Pharmaceuticals by comparing valuation metrics of similar companies.Virpax Pharmaceuticals is currently under evaluation in retained earnings category among its peers.
Virpax Fundamentals
| Return On Equity | -23.65 | ||||
| Return On Asset | -1.35 | ||||
| Current Valuation | (1.21 M) | ||||
| Shares Outstanding | 1.24 M | ||||
| Shares Owned By Insiders | 0.96 % | ||||
| Shares Owned By Institutions | 0.41 % | ||||
| Number Of Shares Shorted | 577.07 K | ||||
| Price To Book | 0.48 X | ||||
| EBITDA | (12.08 B) | ||||
| Net Income | (12.07 B) | ||||
| Cash And Equivalents | 26.06 M | ||||
| Cash Per Share | 2.22 X | ||||
| Total Debt | 2.47 B | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 11.84 X | ||||
| Book Value Per Share | (1.53) X | ||||
| Cash Flow From Operations | (16.71 B) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (71.00) X | ||||
| Target Price | 3.0 | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 831.85 K | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (71.61 B) | ||||
| Working Capital | (913.76 K) | ||||
| Net Asset | 1.56 B |
About Virpax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Virpax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virpax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virpax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Virpax Pink Sheet
If you are still planning to invest in Virpax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virpax Pharmaceuticals' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |